What biomarker testing is recommended for locally advanced Lung Cancer

Biomarker Testing for Locally Advanced Lung Cancer

Based on the NCCN Guidelines, biomarker testing is an important part of determining your treatment options for locally advanced lung cancer. Let me explain what's typically recommended and why.

Why Biomarker Testing Matters

According to the NCCN Guidelines for Patients: Early and Locally Advanced Non-Small Cell Lung Cancer, biomarker tests look for biological clues—or markers—that differ between people's cancers. This is crucial because a treatment that helps one person might not help another. Your care team uses these results to decide which systemic therapies (whole-body drug treatments) are options before and after surgery.

Recommended Biomarkers for Locally Advanced NSCLC

The NCCN Guidelines recommend testing for several key biomarkers:

Driver Mutations (genetic changes that fuel cancer growth)

These are found in at least 1 in 3 people with lung adenocarcinoma:

• EGFR mutations – Changes in the EGFR receptor that make cancer cells grow quickly. This is one of the most common driver mutations.
• ALK rearrangements – A fusion of genes that drives cancer growth
• ROS1 rearrangements – Another gene fusion associated with cancer growth
• BRAF mutations – Specifically the p.V600E mutation
• KRAS mutations – A prognostic marker (indicates how the cancer may behave)
• METex14 skipping mutations – A specific type of genetic change
• ERBB2 (HER2) mutations – Similar to breast cancer biomarkers
• NTRK1/2/3 fusions – Gene fusions that can be targeted
• RET rearrangements – Another actionable gene fusion

Immune Biomarker

• PD-L1 level – A protein on cancer cell surfaces that helps them hide from your immune system. Testing this helps determine if immunotherapy might be effective for you.

How Testing Is Done

According to the NCCN Guidelines, biomarker tests are performed on:

• Tumor tissue removed during biopsy or surgery (preferred method)
• Blood samples in some cases (called "liquid biopsy" or plasma circulating tumor DNA testing)

The NCCN Guidelines note that broad molecular profiling—testing for multiple biomarkers at once using methods like next-generation sequencing (NGS)—is strongly recommended. This comprehensive approach helps ensure you don't miss any actionable mutations.

Important Considerations

Tissue is preferred for diagnosis: The NCCN Guidelines emphasize that tissue should be used to diagnose lung cancer. Blood-based testing can be helpful in specific situations, such as when:

• You're not medically fit for invasive tissue sampling, OR
• There isn't enough tissue for molecular analysis (and follow-up tissue testing will be done if no driver mutation is found)

Testing takes time: Because many genes are tested simultaneously, results can take up to 3 weeks.

What if no biomarkers are found? Some lung cancers don't have known biomarkers with available treatments. In these cases, treatment options are based on your lung cancer cell type.

Questions to Ask Your Care Team

1. Which biomarkers has my tumor been tested for? Make sure comprehensive testing was done.
2. When will my biomarker results be available? This helps you plan your treatment timeline.
3. Do any of my results show driver mutations? If yes, ask which targeted therapies might be options.
4. What is my PD-L1 level, and what does it mean for my treatment?
5. If biomarker testing wasn't done, why not? Ensure you understand the reasoning.
6. Can I get a copy of my pathology report and biomarker results? You have the right to your [ID removed]

Why This Matters for Your Treatment

According to the NCCN Guidelines, biomarker results directly influence whether you're eligible for:

• Targeted therapies (drugs designed to attack specific mutations)
• Immunotherapies (drugs that help your immune system fight cancer)
• Chemotherapy (traditional cancer drugs)

Your oncologist will use these results along with your overall health, stage of disease, and other factors to recommend the best approach for YOUR specific situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.